Canada Markets close in 3 hrs 51 mins

First Wave BioPharma, Inc. (FWBI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.7800-0.3800 (-7.36%)
As of 12:08PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close5.1600
Open5.1000
Bid4.7600 x 3100
Ask4.8300 x 1400
Day's Range4.6550 - 5.3000
52 Week Range3.0100 - 348.6000
Volume201,136
Avg. Volume526,810
Market Cap4.756M
Beta (5Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-14.1880
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
  • GlobeNewswire

    First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

    Patient dosing expected to begin in mid-February with topline data anticipated by mid-2023BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the first patient was screened for the Phase 2 SPAN clinical trial investigating an enhanced enteric micro

  • GlobeNewswire

    First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

    Patient screening to initiate; topline data expected by mid-2023BOCA RATON, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will initiate its planned Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation for adrulipase

  • GlobeNewswire

    First Wave BioPharma to Present at the BIO CEO & Investor Conference

    BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Details of the presentation are as fo